HLA typing and nomenclature
In one sentence
Human leukocyte antigen typing identifies inherited alleles, whose standardized names describe progressively more detailed sequence differences.
The intuition
A human leukocyte antigen (HLA) name is a precise part number. “HLA-A” identifies a family of peptide-display molecules. “HLA-A*02:01” specifies more of the sequence. A predictor or engineered receptor tested with one part number cannot automatically be transferred to another.
Typing tells us which parts a person can inherit. It does not tell us whether a particular tumor still makes those parts, displays the proposed peptide, or is recognized by a T cell.
How it works
In an allele name such as HLA-A*02:01:01:01, the fields have distinct meanings:
| Part of the name | Meaning |
|---|---|
HLA-A | The HLA gene |
02 | An allele group, often related to a serological antigen grouping |
01 after the first colon | Distinguishes protein sequences within that group |
| The third field | Distinguishes synonymous coding-sequence differences |
| The fourth field | Distinguishes differences in noncoding sequence |
An optional suffix carries additional information: for example, N indicates a null allele and L indicates low expression. A name without a suffix is not a measurement of how much HLA a particular cancer cell expresses. Read the laboratory's resolution, ambiguity notes and methods as well as the printed name. A two-field result does not necessarily settle every sequence or expression question.
People generally inherit one copy of each HLA gene from each parent. A report can therefore list two alleles at a locus; identical inherited alleles can appear as the same name. Class I and class II typing describe different display molecules and do not substitute for one another.
For a tumor-targeting project, keep four separate observations: inherited typing, retention and expression in the tumor, peptide display, and receptor recognition. Tumor loss of an allele or changes in antigen-processing machinery can interrupt that chain after an accurate typing result.
Why it matters in cancer
Peptide prediction and many T-cell receptor approaches depend on a particular HLA context. An “HLA-matched” label is therefore a starting condition, rather than a complete demonstration of targetability. Trial eligibility may also specify a particular allele and an accepted testing method; a similar-looking name is insufficient.
Worked example
A fictional report lists HLA-A*02:01 and HLA-A*24:02. A candidate is predicted to bind A02:01. A second laboratory tests a receptor against the same peptide on A24:02.
Those results concern different peptide–HLA pairs. Before combining them, ask whether the receptor was tested on A*02:01 and whether the tumor displays that pair. The report does not make the two HLA molecules interchangeable.
Common confusions
- A shared first field, such as
02, does not establish identical proteins. - Typing is not a tumor-expression or peptide-display assay.
- A negative display assay does not by itself prove the inherited typing was wrong.
- A typing result cannot establish clinical benefit from an HLA-restricted therapy.
Related concepts
Sources and scope
Source-checked October 9, 2026. The report is fictional. This page teaches how to read a name, rather than how to interpret an individual laboratory result or establish trial eligibility. Expert and learner review remain pending.
- Official HLA nomenclature: naming alleles, for allele fields and expression suffixes.
- IPD-IMGT/HLA database, the curated sequence and nomenclature resource.
- Sarkizova and colleagues: primary peptide–HLA presentation study, for allele-specific presentation modeling.